PM
NUVB icon

Prosight Management’s Nuvation Bio NUVB Stock Holding History

Prosight Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-250,000
Closed -$910K – 53
2024
Q1 		$910K Sell
250,000
-1,800,000
-88% -$3.46M 0.25% 39
2023
Q4 		$3.1M Buy
2,050,000
+1,000,000
+95% +$1.29M 1.24% 20
2023
Q3 		$1.41M Sell
1,050,000
-50,000
-5% -$83.2K 0.45% 34
2023
Q2 		$1.98M Buy
+1,100,000
New +$1.87M 0.58% 29
2021
Q3 		– Sell
-91,694
Closed -$854K – 50
2021
Q2 		$854K Buy
+91,694
New +$1.05M 0.53% 36

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Prosight Management's NUVB Position: Q2 2024 in Review

Prosight Management sold out of Nuvation Bio (NUVB) in Q2 2024, closing a stake of 250,000 shares — an estimated $910K sold.

Prosight Management first reported a position in NUVB in Q2 2021 and held it in 5 quarters. The position peaked at $3.1M in Q4 2023. 148 funds tracked by Wall St. Rank hold NUVB as of Q2 2024.

  • Prosight Management reported no remaining Nuvation Bio position as of Q2 2024 after selling out during the quarter.
  • Prosight Management sold 250,000 Nuvation Bio shares in Q2 2024, an estimated $910K.
  • Prosight Management first reported a position in Nuvation Bio in Q2 2021 and held it in 5 quarters.
  • Prosight Management's Nuvation Bio position peaked at $3.1M in Q4 2023.
  • 148 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2024.

Based on Prosight Management's 13F filing for Q2 2024, filed 14 Aug 2024.